ClinicalTrials.gg
CompletedNCT00737529EMERGEUpdated Dec 13, 2018Results posted

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

A Phase 2 interventional study of lenalidomide in Mantle Cell Lymphoma, sponsored by Celgene. Completed at 70 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-13.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
134
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell — 5 open to participants now, 8 under way, none of them phase 3. Lenalidomide · Lymphoma, Mantle-Cell.

Enrollment
5th of 43
134 · median 39
Started
2008
with 3 others
Phase 2
18 of 44
3 open now
Registered
6th of 44
by date
Lead sponsor
4 of 44
Celgene

Among the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, this one is the 5th largest by enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2008, is one of 18 in phase 2, and was the 6th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of Lenalidomide (Revlimid (R)) in subjects with mantle cell lymphoma who have relapsed, progressed or are refractory to bortezomib.

Read the detailed description

Follow up phase will continue until either 100% of the patients have died, are lost to follow up or have withdrawn consent or a maximum of 4 years from the last patient enrolled, whichever comes first. All other efficacy and safety endpoints will be updated at this time. In the unlikely event that the study will be closed and patients are still responding to treatment at this time, Celgene will discuss with the treating physicians options to provide further treatment to the patient after study closure in line with local regulation.

Follow up for second primary malignancies and OS will continue until 100% of the patients have died, are lost to follow up, have withdrawn consent, or a maximum of 5 years from the last patient enrolled, whichever comes first.

10 October 2017: In regard to the last subject last visit date/study completion date, the prolongation of timelines is due to the bridging of a treatment gap for a patient responding to study medication until non-study medication is available.

03

Conditions studied

  • Mantle Cell Lymphoma

Keywords

  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • CC-5013
  • Revlimid
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven mantle cell lymphoma
  • Patients must have documents , refractory or PD after treatment with bortezomib
  • Must have measureable disease on cross sectional imaging by CT
  • (ECOG) performance score 0,1 or 2
  • Willing to follow pregnancy precautions

Exclusion criteria

Exclusion Criteria:

  • Any of the following laboratory abnormalities

    • (ANC) \< 1,500 cells/mm3 (1.5 x 109/L)
    • count \< 60,000/mm3 (60 x 109/L)
    • Serum /Serum glutamic oxaloacetic transaminase(AST/SGOT) or alanine transaminase/Serum glutamic pyruvic transaminase (ALT/SGPT) > 3.0 x (ULN), except in patients with documented liver involvement by lymphoma.
    • Serum total > 1.5 x ULN, except in cases of Gilbert's Syndrome and documented liver involvement by lymphoma.
    • Calculated (Cockcroft-Gault formula) of \< 30 mL /min
    • Patients who are candidates for high dose chemotherapy/ stem cell transplant are not eligible
    • History of active central nervous system (CNS) lymphoma within the previous 3 months
    • Subjects not willing or unable to take deep vein thrombosis (DVT) prophylaxis
    • Prior history of , other than MCL, unless the patient has been free of the disease for ≥ 3 years
    • Positive (HIV) or active or C
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Single agent Lenalidomide Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but \< 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal.

    Drug: lenalidomide

Interventions

  • 25mg oral capsules continuous days 1-21 each of a 28 day cycle

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC)

    Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed, or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses.

    Time frame: From Day 1 of study treatment to progession or early treatment discontinuation; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days.

  2. Kaplan Meier Estimate of Duration of Response (DoR) According to the Independent Review Committee

    Kaplan Meier estimate for the duration of response (DoR) was calculated from the date of the first occurrence of initial response for responders (demonstrating evidence of at least a PR) to the date of first documented disease progression (any new lesion or increase by ≥ 50% of previously involved sites from nadir) or death (without documented progression) for participants who responded; participants who had not progressed (or died) were censored at the last valid assessment.

    Time frame: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days.

Secondary outcomes

  1. Percentage of Participants With a Complete Response (CR) /Complete Response Unconfirmed (CRu) According to the Independent Review Committee

    The percentage of participants whose best response was CR or CRu. Participants who had discontinued before CR/CRu was observed, or changed to other anti-lymphoma treatments before a CR/CRu response had been observed, were considered as non-responders. CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow.

    Time frame: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days

  2. Kaplan Meier Estimate of Duration of Complete Response (DoCR) (CR+CRu) According to the Independent Review Committee

    Kaplan Meier estimates for the duration of CR/CRu was calculated from the date of the first occurrence of CR/CRu to the date of documented disease progression or death (without documented progression) for participants who obtained a CR/CRu; participants who had not progressed (or died) were censored at the last valid assessment.

    Time frame: From Day 1 of study drug to progression or early discontinuation; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months

  3. Kaplan-Meier Estimate of Progression-Free Survival (PFS) According to the Independent Review Committee

    Kaplan Meier estimates of PFS was defined as the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever comes first. If a participant had not progressed or died, PFS was censored at the time of last adequate assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last adequate tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment.

    Time frame: From Day 1 of study drug to first documented date of disease progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months

  4. Kaplan Meier Estimate of Time to Progression (TTP) According to the Independent Review Committee

    Kaplan Meier estimate of time to progression was calculated as time from the start of the study drug therapy to the first observation of disease progression. Participants who died without progression were censored at the date of death; otherwise, the censoring rules presented above for PFS applied to the analysis of TTP. Progressive Disease(PD): Appearance of new lesion or increase by ≥50% from previously involved sites from nadir

    Time frame: From Day 1 of study drug to first documented time of progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months

  5. Kaplan-Meier Estimate of Time to Treatment Failure (TTF) According to the Independent Review Committee

    Time to treatment failure (TTF) was calculated from the start of study drug therapy to early discontinuation from treatment due to any cause, including disease progression, toxicity, or death and was based on site-reported data.

    Time frame: From Day 1 of study drug to first documented time of treatment failure; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days

  6. Time to Response (TTR)

    Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants.

    Time frame: From Day 1 of study drug to time of first documented PR or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days

  7. Time to Complete Response (CR+CRu) According to the Independent Review Committee

    Time to Complete Response (CR+CRu) was defined as the time from the first dose of study drug to the date of the first occurrence of at least CRu and was calculated only for participants with CR or CRu.

    Time frame: From Day 1 of study drug to first documented CR/CRu or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days

  8. Overall Survival (OS)

    Kaplan Meier estimate of overall survival was calculated from the time the first dose of study drug to death from any cause. Participants who had not died were censored at the last date the participant was known to be alive.

    Time frame: From Day 1 of study drug to first documented date of progressive disease or death; up to the final data cut-off date of 30 March 2017; median duration of follow-up for surviving participants was 62.94 months

  9. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.

    Time frame: From the first dose of lenalidomide through 28 days after the last dose during the follow-up phase; median (minimum, maximum) duration of treatment was 94.0 (1.0, 1950 days)

07

Results

Posted Sep 9, 2013

Participant flow

Participants were enrolled and treated at 42 centers in 12 countries: US/ Puerto Rico, France, Israel, Belgium, Spain, Turkey, Austria, Hungary, Italy, Colombia, Germany, and Singapore.

Participant flow — Overall Study
MilestoneLenalidomide
Started134
Completed1
Not completed133
Withdrew: Disease progression95
Withdrew: Adverse event24
Withdrew: Withdrawal by subject5
Withdrew: Death4
Withdrew: Protocol violation1
Withdrew: Other4

Outcome measures

PrimaryPercentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC)

Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed, or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses.

Time frame:
From Day 1 of study treatment to progession or early treatment discontinuation; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days.
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC)
percentage of participantsLenalidomide
Percentage of Participants Who Achieved an Overall Response According to the Independent Review Committee (IRC)29.9 (22.26 to 38.36)
PrimaryKaplan Meier Estimate of Duration of Response (DoR) According to the Independent Review Committee

Kaplan Meier estimate for the duration of response (DoR) was calculated from the date of the first occurrence of initial response for responders (demonstrating evidence of at least a PR) to the date of first documented disease progression (any new lesion or increase by ≥ 50% of previously involved sites from nadir) or death (without documented progression) for participants who responded; participants who had not progressed (or died) were censored at the last valid assessment.

Time frame:
From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days.
Reported as:
Median · months
Kaplan Meier Estimate of Duration of Response (DoR) According to the Independent Review Committee
monthsLenalidomide
Kaplan Meier Estimate of Duration of Response (DoR) According to the Independent Review Committee16.64 (10.4219 to 29.8191)
SecondaryPercentage of Participants With a Complete Response (CR) /Complete Response Unconfirmed (CRu) According to the Independent Review Committee

The percentage of participants whose best response was CR or CRu. Participants who had discontinued before CR/CRu was observed, or changed to other anti-lymphoma treatments before a CR/CRu response had been observed, were considered as non-responders. CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass \>1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow.

Time frame:
From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days
Reported as:
Number · percentage of participants
Percentage of Participants With a Complete Response (CR) /Complete Response Unconfirmed (CRu) According to the Independent Review Committee
percentage of participantsLenalidomide
Percentage of Participants With a Complete Response (CR) /Complete Response Unconfirmed (CRu) According to the Independent Review Committee9.0 (4.71 to 15.12)
SecondaryKaplan Meier Estimate of Duration of Complete Response (DoCR) (CR+CRu) According to the Independent Review Committee

Kaplan Meier estimates for the duration of CR/CRu was calculated from the date of the first occurrence of CR/CRu to the date of documented disease progression or death (without documented progression) for participants who obtained a CR/CRu; participants who had not progressed (or died) were censored at the last valid assessment.

Time frame:
From Day 1 of study drug to progression or early discontinuation; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
Reported as:
Median · months
Kaplan Meier Estimate of Duration of Complete Response (DoCR) (CR+CRu) According to the Independent Review Committee
monthsLenalidomide
Kaplan Meier Estimate of Duration of Complete Response (DoCR) (CR+CRu) According to the Independent Review Committee24.43 (5.063 to NA)
SecondaryKaplan-Meier Estimate of Progression-Free Survival (PFS) According to the Independent Review Committee

Kaplan Meier estimates of PFS was defined as the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever comes first. If a participant had not progressed or died, PFS was censored at the time of last adequate assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last adequate tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment.

Time frame:
From Day 1 of study drug to first documented date of disease progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
Reported as:
Median · months
Kaplan-Meier Estimate of Progression-Free Survival (PFS) According to the Independent Review Committee
monthsLenalidomide
Kaplan-Meier Estimate of Progression-Free Survival (PFS) According to the Independent Review Committee4.01 (3.6822 to 7.2329)
SecondaryKaplan Meier Estimate of Time to Progression (TTP) According to the Independent Review Committee

Kaplan Meier estimate of time to progression was calculated as time from the start of the study drug therapy to the first observation of disease progression. Participants who died without progression were censored at the date of death; otherwise, the censoring rules presented above for PFS applied to the analysis of TTP. Progressive Disease(PD): Appearance of new lesion or increase by ≥50% from previously involved sites from nadir

Time frame:
From Day 1 of study drug to first documented time of progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
Reported as:
Median · months
Kaplan Meier Estimate of Time to Progression (TTP) According to the Independent Review Committee
monthsLenalidomide
Kaplan Meier Estimate of Time to Progression (TTP) According to the Independent Review Committee5.46 (3.7479 to 9.4685)
SecondaryKaplan-Meier Estimate of Time to Treatment Failure (TTF) According to the Independent Review Committee

Time to treatment failure (TTF) was calculated from the start of study drug therapy to early discontinuation from treatment due to any cause, including disease progression, toxicity, or death and was based on site-reported data.

Time frame:
From Day 1 of study drug to first documented time of treatment failure; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
Reported as:
Median · months
Kaplan-Meier Estimate of Time to Treatment Failure (TTF) According to the Independent Review Committee
monthsLenalidomide
Kaplan-Meier Estimate of Time to Treatment Failure (TTF) According to the Independent Review Committee3.75 (2.3342 to 4.6356)
SecondaryTime to Response (TTR)

Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants.

Time frame:
From Day 1 of study drug to time of first documented PR or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
Reported as:
Median · months
Time to Response (TTR)
monthsLenalidomide
Time to Response (TTR)3.5 (1.7 to 15.9)
SecondaryTime to Complete Response (CR+CRu) According to the Independent Review Committee

Time to Complete Response (CR+CRu) was defined as the time from the first dose of study drug to the date of the first occurrence of at least CRu and was calculated only for participants with CR or CRu.

Time frame:
From Day 1 of study drug to first documented CR/CRu or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
Reported as:
Median · months
Time to Complete Response (CR+CRu) According to the Independent Review Committee
monthsLenalidomide
Time to Complete Response (CR+CRu) According to the Independent Review Committee3.9 (1.9 to 13.0)
SecondaryOverall Survival (OS)

Kaplan Meier estimate of overall survival was calculated from the time the first dose of study drug to death from any cause. Participants who had not died were censored at the last date the participant was known to be alive.

Time frame:
From Day 1 of study drug to first documented date of progressive disease or death; up to the final data cut-off date of 30 March 2017; median duration of follow-up for surviving participants was 62.94 months
Reported as:
Median · months
Overall Survival (OS)
monthsLenalidomide
Overall Survival (OS)19.50 (13.6767 to 25.5781)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug.

Time frame:
From the first dose of lenalidomide through 28 days after the last dose during the follow-up phase; median (minimum, maximum) duration of treatment was 94.0 (1.0, 1950 days)
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
participantsLenalidomide
Any TEAE132
Any TEAE Related to Investigational Product (IP)118
Any TEAE Grade 3-5 AE106
Any TEAE Grade 3 AE101
Any TEAE Grade 4 AE57
Any TEAE Grade 5 AE18
Any Grade 3-5 AE Related to IP90
Any Grade 3 AE Related to IP88
Any Grade 4 AE Related to IP41
Any Grade 5 AE Related to IP2
Any TEAE Serious Adverse Event (SAE)70
Any SAE Related to IP30
Any TEAE Leading to Stopping of IP28
Any Treatment Related AE Leading to Stopping IP16
Any AE Leading to Dose Reduction55
Any AE Leading to IP Interruption81
Any Treatment Related AE Leading to Dose Reduction52
Treatment Related AE Leading to IP Interruption66

Adverse events

Collected over From the first dose of 1enalidomide through 28 days after the last dose of lenalidomide; (maximum duration of study drug was 1940 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide106/134 (79.1%)70/134 (52.2%)125/134 (93.3%)
Most frequent serious events
Showing 10 of 95
Most frequent serious events
EventLenalidomide
PNEUMONIAInfections and infestations8/134
FEBRILE NEUTROPENIABlood and lymphatic system disorders7/134
HYPOTENSIONVascular disorders7/134
PYREXIAGeneral disorders6/134
MANTLE CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)6/134
SQUAMOUS CELL CARCINOMA OF SKINNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/134
ABDOMINAL PAINGastrointestinal disorders4/134
PNEUMONIA BACTERIALInfections and infestations4/134
DEHYDRATIONMetabolism and nutrition disorders4/134
DYSPNOEARespiratory, thoracic and mediastinal disorders4/134
Most frequent other events
Showing 10 of 47
Most frequent other events
EventLenalidomide
NEUTROPENIABlood and lymphatic system disorders68/134
THROMBOCYTOPENIABlood and lymphatic system disorders51/134
FATIGUEGeneral disorders47/134
DIARRHOEAGastrointestinal disorders45/134
ANAEMIABlood and lymphatic system disorders42/134
NAUSEAGastrointestinal disorders41/134
COUGHRespiratory, thoracic and mediastinal disorders41/134
PYREXIAGeneral disorders30/134
RASHSkin and subcutaneous tissue disorders30/134
DYSPNOEARespiratory, thoracic and mediastinal disorders24/134

Baseline characteristics

The baseline characteristics are from the participants assesed within the intent to treat population (ITT), which included all enrolled participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(Years)Lenalidomide
Mean67.2 ± 8.38
Age, Customized
Age, Customized(Participants)Lenalidomide
<6549
≥ 6585
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide
Female26
Male108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide
White or Caucasian128
Asian3
Black or African American1
Other2
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Lenalidomide
0 = (Fully Active)43
1 = (Restrictive but ambulatory)73
2 = (Ambulatory but unable to work)17
3 = (Limited self care)1
4 = (Completely Disabled)0
Renal function at baseline
Renal function at baseline(Participants)Lenalidomide
Normal (CrCl > = 60 mL/min)99
Moderate Renal Insufficiency (CrCl ≥ 30 and < 60mL28
Severe Renal Insufficiency (CrCl < 30 mL/min)1
Missing6
Duration of Mantle Cell Lymphoma
Duration of Mantle Cell Lymphoma(years)Lenalidomide
<3 years52
≥ 3 years82
MCL (Ann Arbor) Stage at Diagnosis
MCL (Ann Arbor) Stage at Diagnosis(Participants)Lenalidomide
I2
II5
III19
IV105
Missing3

4 further baseline measures are reported on the registry.

08

Study locations

70 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • UCSD Moores Cancer Center
    La Jolla, California 92093, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • Tower Cancer Research Foundation
    Los Angeles, California 90211, United States
  • Boca Raton Community Hospital, Inc., Research Dept.
    Boca Raton, Florida 33486, United States
  • Pasco Hernando Oncology Associates, PA
    Brooksville, Florida 34613, United States
  • Broward General Medical Center
    Fort Lauderdale, Florida 33316, United States
  • MD Anderson Cancer Center, Orlando Regional Healthcare
    Orlando, Florida 32806, United States
  • Lake County Oncology and Hematology
    The Villages, Florida 32159, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Loyola University Medical Center - Smith
    Maywood, Illinois 60153, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46202, United States
  • Alvin and Lois Lapidus Cancer Institute Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • University of Massachusetts Medical Center
    Worcester, Massachusetts 01655, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201-2014, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University Siteman Cancer Center
    Saint Louis, Missouri 63110, United States
  • University of Nebraska
    Omaha, Nebraska 68198-7680, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • NYU School of Medicine
    New York, New York 10016, United States
  • University of Rochester Cancer Center, James P. Wilmot Cancer Center
    Rochester, New York 14642, United States
  • Presbyterian Hospital
    Charlotte, North Carolina 28204, United States
  • Temple University School of Medicine
    Philadelphia, Pennsylvania 19140, United States
  • Hillman Cancer Institute at UPMC
    Pittsburgh, Pennsylvania 15232, United States
  • South Carolina Cancer Specialists
    Hilton Head Island, South Carolina 29926, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • University of Tennessee Cancer Institute
    Memphis, Tennessee 38104, United States
  • University of Virginia Cancer Center Clinical Trials Office
    Charlottesville, Virginia 22908, United States
  • Universitaetsklinik Innsbruck
    Innsbruck, 6020, Austria
  • Landeskrankenhaus Salzburg
    Salzburg, 5020, Austria
  • Medical University of Vienna
    Vienna, 1090, Austria
  • AZ Sint-Jan AV Brugge
    Brugge, 8000, Belgium
  • UZ Gent
    Gent, 9000, Belgium
  • Universitair Ziekenhuis Leuven, Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Hospital Universitario San Ignacio
    Bogota, Colombia
  • Oncologos del occidente S.A.
    Pereira, Colombia
  • Hopital Sud, CHU d'Amiens
    Amiens, 80054, France
  • Institut Bergonie
    Bordeaux, 33076, France
  • Hopital Henri Mondor
    Créteil, 94010, France
  • Hopital Emile Muller
    Mulhouse, 68070, France
  • Hopital Cochin
    Paris, 75014, France
  • Institut Curie
    Paris, 75248, France
  • Hopital Robert Debre
    Reims Cedex, 51092, France
  • Institut de Cancerologie de la Loire
    Saint Jean Priest En Jarez, 42277, France
  • Hopital Hautepierre
    Strasbourg, 67098, France
  • University Hospital Wuerzburg
    Wuerzburg, 97080, Germany
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
    Debrecen, 4032, Hungary
  • University of Debrecen, DEOEC, Institute of Internal Medicine
    Debrecen, 4032, Hungary
  • Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat
    Gyor, 9024, Hungary
  • Kaposi Mor Oktato Korhaz
    Kaposvar, 7400, Hungary
  • Rambam Medical Center
    Haifa, 35254, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • Rabin Medical Center
    Petch Tikva, 49100, Israel
  • Sheba Medical Center
    Tel Hashomer, 52621, Israel
  • Universita Federico II di Napoli Nuovo Policlinico
    Napoli, 80131, Italy
  • Ospedale Civile dello Spirito Santo
    Pescara, 65124, Italy
  • Universita Cattololica del Sacro Cuore
    Roma, 00168, Italy
  • Centro De Cancer, Hospital Espanol Auxilio De Puerto Rico
    San Juan, 00919, Puerto Rico
  • Singapore General Hospital
    Singapore, 169608, Singapore
  • Hospital General De Elche
    Alicante, 03203, Spain
  • Duran i Reynals Institut Catala d'Oncologia
    L'Hospitalet de Llobregat, 08907, Spain
  • Hospital Clinico Universitario de Salamanca
    Salamanca, 37003, Spain
  • Hospital Universitario La Fe
    Valencia, 46009, Spain
  • Gazi Universitesi
    Besevler Ankara, 06500, Turkey
  • Istanbul Universitesi Istanbul
    Istanbul, 34390, Turkey
  • Ankara Universitesi Tip Fakultesi
    Sihhiye Ankara, 06100, Turkey
  • Royal Cornwall Hospitals Trust
    Truro, TR1 3LJ, United Kingdom
09

References and documents

Publications

  • Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, Zhang L, Cicero S, Fu T, Witzig TE. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013 Oct 10;31(29):3688-95. doi: 10.1200/JCO.2013.49.2835. Epub 2013 Sep 3. PubMed 24002500 ↗
  • Goy A, Kalayoglu Besisik S, Drach J, Ramchandren R, Robertson MJ, Avivi I, Rowe JM, Herbrecht R, Van Hoof A, Zhang L, Cicero S, Fu T, Witzig T. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015 Aug;170(4):496-503. doi: 10.1111/bjh.13456. Epub 2015 Apr 28. PubMed 25921098 ↗
  • Witzig TE, Luigi Zinzani P, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017 Oct;92(10):E575-E583. doi: 10.1002/ajh.24854. Epub 2017 Aug 28. PubMed 28699256 ↗
  • San-Miguel JF, Richardson PG, Gunther A, Sezer O, Siegel D, Blade J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013 Oct 10;31(29):3696-703. doi: 10.1200/JCO.2012.46.7068. Epub 2013 Sep 9. PubMed 24019544 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Apr 2016, 87 months.

Of 30 industry-sponsored phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's 87 months is above that.

Counting every sponsor, half of 183 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2008
First posted
Aug 19, 2008
StartActual
Dec 22, 2008
Primary completionActual
Apr 6, 2016
CompletionActual
Nov 8, 2017
Results first posted
Sep 9, 2013
Last update
Dec 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00737529
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Aug 19, 2008
Start date
Dec 22, 2008
Primary completion
Apr 6, 2016
Completion
Nov 8, 2017
Results posted
Sep 9, 2013
Last update
Dec 13, 2018

Study contacts

Lei Zhang, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion